重组人尿激酶原联合替罗非班对经PCI治疗ASTEMI患者心功能及预后的影响  

Influence of recombinant human prourokinase combined tirofiban on cardiac function and prognosis in ASTEMI patients undergoing PCI

作　　者：贾涵铄 江涛[1] 王德良[1] 裴建行[1] JIA Han-shuo;JIANG Tao;WANG De-liang;PEI Jian-xing(Department of Cardiology,Baoding Second Central Hospital,Baoding,Hebei,072750,China)

机构地区：[1]保定市第二中心医院心内科,河北保定072750

出　　处：《心血管康复医学杂志》2024年第4期461-465,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：保定市科技计划项目(2041ZF032)。

摘　　要：目的:探究重组人尿激酶原联合替罗非班治疗对经急诊经皮冠状动脉介入治疗(PCI)急性ST段抬高型心肌梗死(ASTEMI)患者心功能及预后的影响。方法:选择2019年6月~2020年12月本院接诊的156例行PCI术ASTEMI患者,根据随机数字表法均分为对照组(急诊PCI术中给予替罗非班注射)和研究组(在对照组基础上行重组人尿激酶原注射)。两组患者急诊PCI术前后用药一致。对比两组患者手术前后心肌梗死溶栓治疗(TIMI)血流、心肌灌注(TMPG)分级、PCI术前、后一周心功能指标,随访1年主要不良心血管事件(MACE)及不良反应发生情况。结果:手术后,与对照组比较,研究组TIMI血流3级(51.28%比83.00%)和TMPG分级3级(51.28%比84.62%)比例、术后1周左室射血分数(LVEF)[(44.26±3.45)%比(49.17±2.92)%]均显著提高,术后1周左心室舒张末期内径(LVEDd)[(56.47±2.54)mm比(51.32±2.55)mm]、左心室收缩末期内径(LVESd)[(41.86±2.49)mm比(36.01±1.68)mm]、随访1年内MACE发生率(24.36%比7.69%)和不良反应发生率(10.26%比1.28%)均显著下降(P<0.05或<0.01)。结论:经PCI治疗ASTEMI患者采用重组人尿激酶原联合替罗非班治疗后,可显著改善患者心功能,降低MACE与不良反应发生率,改善预后,值得临床借鉴。Objective:To investigate the effect of recombinant human prourokinase combined with tirofiban on cardiac function and prognosis in patients with acute ST-segment elevation myocardial infarction(ASTEMI)undergoing emergency percutaneous coronary intervention(PCI).Methods:A total of 156 ASTEMI patients undergoing PCI treated in our hospital from June 2019 to December 2020 were selected.They were equally divided into control group(received tirofiban injection during emergency PCI)and study group(received recombinant human prourokinase injection based on control group)according to random number table method.Two groups received the same medication before and after emergency PCI.Thrombolysis in myocardial infarction(TIMI)flow,TIMI myocardial perfusion grade(TMPG)before and after PCI,cardiac function indexes before and one week after PCI,incidence of major adverse cardiovascular events(MACE)and adverse reactions within 1-year follow-up were compared between two groups.Results:After PCI,compared with control group,there were significant rise in proportions of TIMI flow grade 3(51.28%vs.83.00%)and TMPG grade 3(51.28%vs.84.62%),left ventricular ejection fraction(LVEF)one week after PCI[(44.26±3.45)%vs.(49.17±2.92)%],and significant reductions in left ventricular end-diastolic diameter(LVEDd)[(56.47±2.54)mm vs.(51.32±2.55)mm],left ventricular end-systolic diameter(LVESd)[(41.86±2.49)mm vs.(36.01±1.68)mm]one week after PCI,incidence rates of MACE(24.36%vs.7.69%)and adverse reactions(10.26%vs.1.28%)within 1-year follow-up in study group(P<0.05 or<0.01).Conclusion:Recombinant human prourokinase combined with tirofiban can significantly improve cardiac function,reduce the incidence rates of MACE and adverse reactions,and improve the prognosis in ASTEMI patients after PCI,which is worthy of clinical reference.

关 键 词：心肌梗死 血管成形术 气囊 冠状动脉 预后 替罗非班 

分 类 号：R542.22[医药卫生—心血管疾病]